000119414 001__ 119414
000119414 005__ 20240228134939.0
000119414 0247_ $$2doi$$a10.1007/s00259-013-2525-5
000119414 0247_ $$2pmid$$apmid:24072344
000119414 0247_ $$2pmc$$apmc:PMC3843747
000119414 0247_ $$2ISSN$$a0340-6997
000119414 0247_ $$2ISSN$$a1432-105X
000119414 0247_ $$2ISSN$$a1619-7070
000119414 0247_ $$2ISSN$$a1619-7089
000119414 0247_ $$2altmetric$$aaltmetric:3879866
000119414 037__ $$aDKFZ-2017-00156
000119414 041__ $$aeng
000119414 082__ $$a610
000119414 1001_ $$0P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aAfshar-Oromieh, Ali$$b0$$eFirst author$$udkfz
000119414 245__ $$aComparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer.30
000119414 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2014
000119414 3367_ $$2DRIVER$$aarticle
000119414 3367_ $$2DataCite$$aOutput Types/Journal article
000119414 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1487772407_1761
000119414 3367_ $$2BibTeX$$aARTICLE
000119414 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119414 3367_ $$00$$2EndNote$$aJournal Article
000119414 520__ $$aPositron emission tomography (PET) with choline tracers has found widespread use for the diagnosis of prostate cancer (PC). However, choline metabolism is not increased in a considerable number of cases, whereas prostate-specific membrane antigen (PSMA) is overexpressed in most PCs. Therefore, a (68)Ga-labelled PSMA ligand could be superior to choline tracers by obtaining a high contrast. The aim of this study was to compare such a novel tracer with standard choline-based PET/CT.Thirty-seven patients with biochemical relapse of PC [mean prostate-specific antigen (PSA) 11.1 ± 24.1 ng/ml, range 0.01-116] were retrospectively analysed after (18)F-fluoromethylcholine and (68)Ga-PSMA PET/CT within a time window of 30 days. Radiotracer uptake that was visually considered as PC was semi-quantitatively analysed by measuring the maximum standardized uptake values (SUVmax) of the scans acquired 1 h after injection of (68)Ga-PSMA complex solution (median 132 MBq, range 59-263 MBq) and (18)F-fluoromethylcholine (median 237 MBq, range 114-374 MBq), respectively. In addition, tumour to background ratios were calculated.A total of 78 lesions characteristic for PC were detected in 32 patients using (68)Ga-PSMA PET/CT and 56 lesions were detected in 26 patients using choline PET/CT. The higher detection rate in (68)Ga-PSMA PET/CT was statistically significant (p=0.04). In five patients no lesion was found with both methods. All lesions detected by (18)F-fluoromethylcholine PET/CT were also seen by (68)Ga-PSMA PET/CT. In (68)Ga-PSMA PET/CT SUVmax was clearly (>10 %) higher in 62 of 78 lesions (79.1 %) and the tumour to background ratio was clearly (>10 %) higher in 74 of 78 lesions (94.9 %) when compared to (18)F-fluoromethylcholine PET/CT.(68)Ga-PSMA PET/CT can detect lesions characteristic for PC with improved contrast when compared to standard (18)F-fluoromethylcholine PET/CT, especially at low PSA levels.
000119414 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000119414 588__ $$aDataset connected to CrossRef, PubMed,
000119414 650_7 $$2NLM Chemicals$$aAntigens, Surface
000119414 650_7 $$2NLM Chemicals$$aGallium Radioisotopes
000119414 650_7 $$2NLM Chemicals$$aLigands
000119414 650_7 $$2NLM Chemicals$$afluoromethylcholine
000119414 650_7 $$0EC 3.4.17.21$$2NLM Chemicals$$aGlutamate Carboxypeptidase II
000119414 650_7 $$0EC 3.4.17.21$$2NLM Chemicals$$aglutamate carboxypeptidase II, human
000119414 650_7 $$0N91BDP6H0X$$2NLM Chemicals$$aCholine
000119414 7001_ $$0P:(DE-HGF)0$$aZechmann, Christian M$$b1
000119414 7001_ $$0P:(DE-HGF)0$$aMalcher, Anna$$b2
000119414 7001_ $$0P:(DE-He78)331382460d902d1341dc73db8b990f97$$aEder, Matthias$$b3$$udkfz
000119414 7001_ $$0P:(DE-HGF)0$$aEisenhut, Michael$$b4
000119414 7001_ $$0P:(DE-HGF)0$$aLinhart, Heinz G$$b5
000119414 7001_ $$0P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aHolland-Letz, Tim$$b6$$udkfz
000119414 7001_ $$aHadaschik, Boris A$$b7
000119414 7001_ $$0P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aGiesel, Frederik$$b8$$udkfz
000119414 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b9$$udkfz
000119414 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b10$$eLast author$$udkfz
000119414 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-013-2525-5$$gVol. 41, no. 1, p. 11 - 20$$n1$$p11 - 20$$tEuropean journal of nuclear medicine and molecular imaging$$v41$$x1619-7089$$y2014
000119414 909CO $$ooai:inrepo02.dkfz.de:119414$$pVDB
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)440aad6e9a60396ff0bcd7c2862db18c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)331382460d902d1341dc73db8b990f97$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)457c042884c901eb0a02c18bb1d30103$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5ca7e97b2769bb97f8c73431c6566b94$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000119414 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000119414 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000119414 9141_ $$y2014
000119414 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119414 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119414 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119414 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119414 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119414 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2015
000119414 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119414 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119414 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119414 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119414 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000119414 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119414 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2015
000119414 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lKKE Nuklearmedizin$$x0
000119414 9201_ $$0I:(DE-He78)E030-20160331$$kE030$$lRadiopharmazeutische Chemie$$x1
000119414 9201_ $$0I:(DE-He78)G100-20160331$$kG100$$lTranslationale Onkologie$$x2
000119414 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x3
000119414 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lKKE Strahlentherapie$$x4
000119414 980__ $$ajournal
000119414 980__ $$aVDB
000119414 980__ $$aI:(DE-He78)E060-20160331
000119414 980__ $$aI:(DE-He78)E030-20160331
000119414 980__ $$aI:(DE-He78)G100-20160331
000119414 980__ $$aI:(DE-He78)C060-20160331
000119414 980__ $$aI:(DE-He78)E050-20160331
000119414 980__ $$aUNRESTRICTED